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Abstract 
Background: Leg ulcers are a frequent complication in patients with the inherited hemoglobin disorders.  In 
thalassemia, the literature is limited, and factors associated with the development of leg ulcers in HbE beta 
thalassemia, the most common form of severe beta thalassemia worldwide, have not previously been reported.    
Methods: We reviewed all available medical records of patients with HbE beta thalassemia to document the 
onset of leg ulcers at the two largest treatment centres in Sri Lanka.  We reviewed the literature to identify 
studies reporting outcomes of interventions for ulcers in severe thalassemia. 
Results: Of a total of 255 actively registered patients with HbE thalassemia in the two centres, 196 patient charts 
were evaluable.  A leg ulcer with a documented date of onset was recorded in 45 (22%) of 196 evaluable 
patients, aged (mean ± SEM) 22.2 ± 1.4 years.  Most had been irregularly transfused; steady state hemoglobin was 
6.4 ± 0.2 g/dL.  Treatment achieving healing in 17 patients included transfusions, antibiotics, oral zinc, wound 
toileting and skin grafting. 
Discussion/Conclusion: Leg ulcers may be more common in HbE beta thalassemia than in other forms of 
thalassemia.  A systematic approach to treatment will be needed to document the prevalence and factors placing 
such patients at risk for leg ulcers.  Controlled trials to evaluate the optimal treatment of this common 
complication are indicated. 
 
Introduction   
Thalassemia is one of the two most common monogenic diseases in the world.  The genotype of Hemoglobin E 
thalassemia (HbE thalassemia) is present in approximately one-half of patients with severe beta thalassemia 
 
 
worldwide, with the highest frequencies observed throughout Asia [1], including Sri Lanka [2]. HbE thalassemia is 
also now the most common form of severe beta thalassemia identified in US newborn screening programs [3].    
 
HbE thalassemia has a highly variable clinical phenotype, ranging from a mild anemia to a clinical course during 
which transfusions may be required from infancy.  Its clinical variability, and the paucity of long-term studies of its 
natural history, makes the optimal management of HbE thalassemia uncertain.  In higher resource countries, most 
patients are regularly transfused [4]; by contrast, many patients in lower-resource countries are transfused 
irregularly, some only during episodes of infection or surgery, or during pregnancy [1,3].  In many such patients, 
complications of anemia and ineffective erythropoiesis are commonly reported.  Complications arising in patients 
with HbE thalassemia [2] that are related primarily to the basic pathophysiology of the disease include 
hepatosplenomegaly, facial deformity, extramedullary erythropoiesis, and a history of serious infection.  We and 
others [2,4,5,6,7] have reported additional complications in HbE thalassemia which may develop following 
splenectomy (including elevated pulmonary artery pressure, increased platelet counts, and venous 
thromboembolism); and those arising from poorly controlled iron loading (including delayed growth and sexual 
maturation, hypothyroidism and diabetes mellitus). 
 
The development of leg ulcers in patients with the inherited hemoglobinopathies may increase disability, and 
disrupt quality of life.  The prevalence and factors influencing leg ulceration has not previously been extensively 
examined in thalassemia, and no previous examination of this complication in those with HbE thalassemia has 
been reported.   
 
We examined all available medical records at the two centers in Sri Lanka managing patients with HbE 
thalassemia, within a cohort of patients observed since 1996 [9].  Our goal was to identify patients who had 
sustained the complication of a leg ulcer, and to determine factors affecting the development of this 
complication.  
   
Methods  
All the available medical records of patients with HbE thalassemia were reviewed over two consecutive months, 
at two centers in Sri Lanka (The National Thalassemia Center, Kurunegala; The Adult Thalassemia Program, 
Ragama) with the highest numbers of patients with HbE thalassemia in the country.  
 
Ethical permission for the study was obtained from University of Colombo and the Central Oxford Research Ethic 
Committee (first obtained in 1996 and extended in 2006, 2013 and 2018). Written informed consent was not 
sought from individual patients, because no experimental intervention was implemented. 
 
Of a total of 255 actively registered patients with HbE thalassemia in the two centers, 59 charts could not be 
located or had incomplete data, usually related to the retention of medical records by patients.  In the 
remaining 196 patient charts, data were collected by two independent reviewers (PC; SJ).  Patients in whom the 
date of onset of a new leg ulcer was documented were included; patients in whom an ulcer was recorded, but the 
date of onset was not documented, were excluded.  When documentation of the record of a leg ulcer was 
considered ambiguous, consensus was reached by both reviewers.   
 
We collected available records of: age; gender; history of onset of the ulcer; description (laterality, location); a 
record of healing, non-healing, and ulcer recurrence (recurrence was ultimately excluded as a variable, because of 
the frequent ambiguity as to whether descriptions of an ulcer at serial visits were related to the original, or a new, 
ulcer); blood transfusion regimen; splenectomy status; estimates of iron overload (serum ferritin concentration); 
hemoglobin and platelet count at ulcer onset; and fetal hemoglobin. No values of reticulocyte counts, LDH and 
bilirubin concentrations were available in most charts, even in infrequently transfused patients in whom 
documentation of trends in these endpoints might have been of interest.  
 
Using data from a larger data base of HbE thalassemia patients currently under development compared selected 
baseline characteristics of 151 patients with no documentation of a leg ulcer to those of the 45 patients of this 




Data were compiled and analyzed by one reviewer (VM). Continuous variables are presented as mean +/- 
standard error of the mean [range]. Discrete variables are presented as number (%) of patients.   
 
To conduct our systematic search of the literature, searched Ovid MEDLINE, Embase, and CINAHL from their 
inception to July 16, 2020, using the keywords “thalassemia” and “leg ulcer” and all appropriate synonyms.  
Studies were included if they evaluated interventions for leg ulcers in patients with severe thalassemia and 
reported quantitative or qualitative outcomes. Articles were excluded if they were not written in English, were 
abstracts or conference papers, did not report original research, or if the full-texts were inaccessible. The 
exception to this was the inclusion of a paper which focused on treatment of leg ulcers in HbE thalassemia but for 
which the full-text was inaccessible; information was obtained from the abstract of the paper [10].  
Results  
The onset of a new leg ulcer was recorded in 45 (22.2%) of 196 evaluable medical records: 188 patients in 
Kurunegala and 8 patients in Ragama.  Patient characteristics are shown in Table 1.  Patients presented with a 
new leg ulcer at a mean age of 22.2 ± 1.4 years, most between age 20 and 29 years (Fig. 1).  The diagnosis of the 
primary disease of HbE thalassemia at age 12.9 ± 1.9 years is consistent with previous findings [2].   
With respect to the factors that may have influenced the development of a leg ulcer, anemia was present in all 
patients.  Steady state hemoglobin, 6.4 ± 0.2 g/dL, was consistent with the larger cohort of patients including 
those without ulcers [2].  Fetal hemoglobin concentration was elevated at 31.7 ± 2.1% and mean serum ferritin 
concentration was 1108 ± 207 ng/mL, both consistent with findings in the larger cohort including patients without 
leg ulcers [2].  Of patients who developed a leg ulcer, 55.6% were receiving transfusions “on demand” during 
periods of infection, intercurrent illness, surgery, and pregnancy only.  The remaining patients had been treated 
with pre-scheduled transfusions, 15.6% regular transfusions (≥8/year) at ulcer onset, and 13.3% irregular 
transfusion (< 8/year).  In 15.6% records, the ongoing regimen of transfusion was undocumented.    
Consistent with the age of patients and the practice of splenectomy which was common prior to 2010 in Sri 
Lanka, over half (53.4%) of patients identified with ulcers had been splenectomised at ulcer diagnosis or 
underwent splenectomy during ulcer treatment; this proportion was also consistent with the larger cohort 
including those without ulcers [2].   
Consistent with post splenectomy status, most patients had elevated platelet counts (mean ± SEM 550.6 ± 53.24 x 
109) at onset of the ulcer.  Hypothyroidism was present in 11.1% patients, and diabetes mellitus in 13.3%, both 
consistent with those in the larger cohort of patients without ulcers [2].  
Overall, 31.1% of patients had a unilateral leg ulcer, 22.2% had bilateral ulcers; in 46.7% of charts, the laterality 
was unrecorded.  The location of ulcers (medial vs. lateral) was also irregularly recorded: 24.4% of patients 
developed ulcers on the ankle; 24.4% ulcers were reported “on the leg”; in the remainder, location was 
inconsistently documented.  Trauma was specifically reported as an inciting factor to the ulcer development in 
15.6% records.  
 
Table 2 shows that a lower proportion (13%) of patients with a history of a leg ulcer had been maintained on a 
regimen of pre-scheduled transfusions, compared to the 151 patients without documentation of a leg ulcer, of 
whom 40% had been maintained on a regimen of pre-scheduled transfusions (P=0.02).  A total of 62% of patients 
with leg ulcers had undergone splenectomy, while 40% of patients with no documentation of a leg ulcer 
undergone splenectomy (P=0.01).  The incidence of diabetes mellitus was higher but not statistically different (at 
the P=0.05 level) in those who developed a leg ulcer (13.3%) when compared to that of 6.8%, in 147 (of 151) 
evaluable patients in whom a leg ulcer was not recorded (P=0.187; OR: 2.11; CI: 0.72-6.16; Table 2).  There was no 
statistically significant difference in initial serum ferritin concentration, the only estimate of iron loading available 
in most patients, between the patients with, and without, a documented leg ulcer. It is important to note that the 
values for the 45-patient cohort are different in Table 2 compared to Table 1 for transfusion status, hemoglobin, 
and serum ferritin concentration.  This is because in Table 1 values at ulcer onset are recorded, whereas in Table 
2, baseline values at first visit are recorded. For splenectomy status, Table 1 shows those who were 
splenectomized before or during ulcer treatment, whereas Table 2 includes lifetime splenectomy status.  
 
Approaches to treatment 
The treatment approach was documented in 22 patients, and undocumented in 23 patients.  Many treatments 
were given contemporaneously, often adding another treatment without analysis of the results of the first 
treatment, resulting in considerable difficulty in assessing the responses to specific treatments.  Monthly 
 
 
transfusions had been initiated after the onset of an ulcer in 16 patients.  Antibiotics were administered (in 7 
patients); in four patients, zinc supplements were introduced at the onset of monthly transfusions.   In three 
patients, “wound toilet treatment” was introduced.  In three patients, surgical skin grafts, and in one patient, oral 
corticosteroids, were prescribed.   
 
Treatment outcomes 
Healing was reported as complete in 17 patients.  Five of the 17 had received transfusions; one had been 
administered antibiotics with zinc supplements; one had been given zinc supplements and “wound toilet 
treatment”; two had undergone skin grafting.  In eight of the 17 patients in whom healing was recorded, the 
treatment that had led to healing was undocumented.   
 
Healing was reported as not complete in 19 patients. Of these, four had been treated with regular transfusions; 
two with a combination of transfusions and antibiotics; one each had been started on one of the following 
regimens: zinc supplements; transfusions and zinc supplements; a skin graft and “wound toilet treatment”; 
transfusions plus hydrocortisone; antibiotics and zinc supplements.  In the other eight patients in whom the ulcer 
was non-healed, treatment(s) were undocumented. 
 
Discussion 
Leg ulceration in patients with the inherited hemoglobinopathies sickle cell disease and thalassemia, is reported 
to increase disability and disrupt quality of life.  The prevalence in sickle cell disease, which is likely influenced by 
climate [11], is widely variable between 2.5% and 80% [12] and has been associated with an increased risk of 
death [13]. Despite this high prevalence and risk, optimal management of leg ulcers in sickle cell disease remains 
uncertain [11,14], with no non-biased, randomised trial data to guide best treatment practices [12].   
Yet an even larger gap exists in thalassemia in which it is difficult even to securely estimate the prevalence of leg 
ulceration. We identified a total of 23 studies which have reported treatments for leg ulcers in patients with 
major forms of beta thalassemia [10, 15-35] and severe alpha thalassemia (Hemoglobin H disease) [36].  
Only one study has focused treatment on patients with HbE thalassemia [10]. Eighteen of the 23 studies were 
published over ten years ago; most were small with a median sample size of one patient, with only three studies 
reporting findings in more than ten patients.  Although the prevalence of leg ulcers may be increased in tropical 
climates, there are relatively few publications in thalassemia from these areas, with one study reported from each 
of India and Pakistan and two from Thailand.  There are no other studies from Sri Lanka which have reported leg 
ulcers in thalassemia.  Overall, outside of Sri Lanka, leg ulcers are reported as more common in thalassemia 
intermedia (with prevalences varying from 4.7% in a single center study [13], to 8% in a large review [12]), than in 
thalassemia major.  Reports of ulcers in Hemoglobin H disease are limited to single patients [14].   
 
Our study is one of few to examine the treatment of leg ulcers in HbE thalassemia, the most common genotype of 
severe beta thalassemia worldwide.  HbE thalassaemia arises from compound heterozygosity of the abnormal 
haemoglobin E and a β-thalassaemia allele, and has a complex pathophysiology derived from globin chain 
imbalance, ineffective erythropoiesis, hemolysis, oxidative damage and shortened red cell survival [38-40]. We 
have previously shown that patients with HbE thalassemia, related to the decreased oxygen affinity of 
Hemoglobin E, have an ability to right-shift their oxygen dissociation curve [41], and related to improved tissue 
oxygenation, HbE thalassemia patients might be expected to have a lower prevalence of leg ulceration compared 
to patients with thalassemia not involving hemoglobin E.  However, nearly one in five evaluable patients in our 
cohort developed a leg ulcer during their clinical course and because we eliminated records in which no date of 
onset of the ulcer was recorded, this almost certainly represents an underestimate and is higher than that 
reported in small studies of other forms of severe beta thalassemia. 
 
In all inherited hemoglobinopathies, one of the primary risk factors influencing ulcer development is likely severe 
untreated, or under-treated, chronic anemia.  Reflecting the transfusion practices of the past 20 years in Sri 
Lanka, anemia is present in all our patients with HbE thalassemia.  Over half of our patients had been treated with 
“on demand” and/or irregularly scheduled, transfusions; one in six had received monthly transfusions.  The 
severity of anemia in patients who developed ulcers (mean steady state hemoglobin 6.4 ± 0.2 g/dL) was not 
different from the group as a whole [2]. In parallel, however, the elevated concentrations of fetal hemoglobin 
were similar to those which may aggravate tissue hypoxia, and possibly increase the formation of leg ulcers, as 
 
 
observed in patients with sickle cell disease [19,21]. While some studies had suggested that elevated 
concentrations of fetal hemoglobin may protect against the development of leg ulcers in patients with sickle cell 
disease [42], as well as with non-transfusion-dependent thalassemia [43], other studies in sickle cell disease have 
suggested a lack of a protective effect of higher fetal hemoglobin or of hydroxyurea, which augments fetal 
hemoglobin, against the development of leg ulcers [13]. In our patients, mean fetal hemoglobin of 31.7% was 
slightly less than that (53.8 ± 7.6%) in the 13 studies of thalassemia patients who developed leg ulcers which have 
reported this variable [15, 18,19,21-23,26,27,29,31-33,35].  
 
Other risk factors for the development of leg ulcers may include ongoing red cell haemolysis resulting in 
consumption of nitric oxide and impaired endothelial function [44].  In patients with HbE thalassemia, significant 
reduction in plasma nitric oxide metabolites and in prostaglandin E2 levels [45], and evidence of markers for 
endothelial cell activation and injury [46], have been reported. In this study reticulocyte counts, LDH and bilirubin 
concentrations were not available in most patients with leg ulcers.  This is by contrast to reports in those with 
sickle cell disease and leg ulcers [47].  Further studies in HbE thalassemia, including prospective analyses in our 
patients, may provide more information about the relationship of these markers of accelerated hemolysis to the 
risk of the development of leg ulcers.  
 
In tropical climates, including Sri Lanka, exposure may lead to higher risk of infection aggravating leg ulcers [48].  
On a related note, trauma has been reported as an inciting incident for the onset of leg ulcers in patients with 
sickle cell disease [9]. One in six of our patients reported trauma as an inciting incident.  Other risk factors may 
also be extrapolated from studies of sickle cell disease in which increased venous pressure, resulting in slow 
healing, has been cited as a risk factor for ulcers [49].  Although no studies in thalassemia have correlated 
elevated venous pressures to leg ulcers, significant elevations in pulmonary artery pressures have been reported 
in HbE thalassemia patients, particularly those who have been splenectomized [50-53]. 
 
A chronic low‐grade hypercoagulable state in sickle cell disease arising from elevated platelet counts and 
increased endothelial adhesion has been reported in sickle cell disease patients who develop leg ulcers [14,54].  
Data suggest that splenectomised patients with HbE thalassemia may also experience a chronic, low‐grade 
hypercoagulable state [55], probably influenced by post-splenectomy elevated platelet counts, reduced levels of 
protein C and protein S, a reactive red cell surface and abnormal endothelium [46,50,56,57], which may be 
ameliorated by blood transfusions [51].  This may increase a propensity for vascular perturbation, consistent with 
the observed increased risk of venous thromboembolism in splenectomized patients with HbE thalassemia [58], 
and of leg ulcers in splenectomized patients with non-transfusion-dependent thalassemia [37]. In our patients, 
more than half of whom had been splenectomised, platelet counts recorded at ulcer onset were elevated at 550.6 
± 53.24 x 10x9, similar to that (587.2 ± 111.2 x10x9/L) in the seven thalassemia ulcer studies in which this 
information was provided [15,16,27,29,32-33,35].  
 
Generally, leg ulcers are a disease of young adults; our patients at diagnosis of the ulcer were 22.2 ± 1.4 years, 
younger than the mean age (30.9 ± 3.6 years) of reported onset of ulcers in patients with other forms of 
thalassemia [16-20,22-23,25-31,35].  
 
One study suggested that iron overload plays a role in the pathophysiology of ulcers through generation of 
oxidative stress, as well as a factor perpetuating chronicity of the ulcer [15].  In our patients, serum ferritin 
concentration at diagnosis of ulcer was elevated at 1108 ± 207 ug/L, similar to the serum ferritin concentration 
(1045 ± 86 ng/mL) of the large cohort with HbE thalassemia [2] and that (1247.0 ± 405.1 ng/mL) in the five studies 
of ulcers in thalassemia which have reported this variable [15,29,30,32,35]. 
In sickle cell disease and thalassemia intermedia, one risk factor influencing ulcer development is likely under-
treated chronic anemia.  Data from a larger data base of HbE thalassemia patients currently under development 
was used to compare selected baseline characteristics of 151 patients with no documentation of a leg ulcer to 
those of the 45 patients of this study.  Some differences were identified which may guide future prospective 
work.  A lower proportion (13%) of patients with a history of a leg ulcer had been maintained on a regimen of pre-
scheduled transfusions, compared to 40% of patients without documentation of a leg ulcer.  Although the initial 
mean hemoglobin concentration in the patients with a documented leg ulcer was not significantly different from 
that in the patients without a leg ulcer, we did not have access to the steady state hemoglobin over time in most 
 
 
patients.  It is possible that, because those with leg ulcers were less regularly transfused, their steady-state 
haemoglobin concentrations would have been lower and their concentrations of fetal hemoglobin higher (both 
representing a possible risk factor for the development of a leg ulcer) than in those without a history of a leg 
ulcer.  Patients with a documented leg ulcer had also undergone splenectomy at a higher rate.  As discussed, 
splenectomy may aggravate a chronic, low‐grade hypercoagulable state [51], probably influenced by post-
splenectomy elevated platelet counts, which were unavailable in most of the larger for comparison.  
 
Finally, it is well recognized that ulcers are common in diabetic patients [59].  while the pathophysiology of HbE 
thalassemia likely represented the primary reason for the development of leg ulcers in these patients, another 
factor representing a risk for the development of leg ulcers in the non-thalassemia population is diabetes mellitus.  
The incidence of diabetes mellitus was higher, but not statistically different (at the P=0.05 level), in those who 
developed a leg ulcer when compared to in 147 (of 151) evaluable patients in whom a leg ulcer was not recorded.  
In further prospective studies it would be interesting to evaluate educational and income levels (on which we 
have no current information) in patients who did or did not develop a leg ulcer; these are reported to influence 
the risk for development of leg ulcers in patients with diabetes in Sri Lanka [60]. 
Treatment outcomes  
Treatment approaches to leg ulcers have been variable in major forms of thalassemia  
Skin grafting has achieved partial healing in some [16,21,30], but not all studies [19].  Using this approach, two of 
our patients achieved complete healing while one did not.  Multiple topical therapies have been used over several 
decades.  Partial or complete healing have been reported using a combination of antibiotics, aluminum acetate, 
pinch grafts, petroleum strips, ace bandages, and an Unna boot [16], ascorbic acid [17], gelatin sponge powder 
[19], eusol and paraffin dressings [14], xanthinol nicotinate [20], perilesional injections of granulocyte-
macrophage colony-stimulating factor [61], and a combination of compression bandages, hydrocolloids and silver-
coated dressings [30].  Failures of healing have been reported with local application of oxygen and silver nitrate 
[18] and topical antibiotics [15].  
 
The most common systemic therapies have included blood transfusions and platelet-derived growth factor.  
Transfusions have been suggested to be non-protective for the development of leg ulcers in sickle cell disease 
[13], but were reported as protective for leg ulcers in patients with NTDT [62].  All studies in thalassemia are 
small, with variable results from rapid healing with a 100% recurrence rate [15], to slower but complete healing 
[29,31], including when combined with antibiotics [35]. One third of our patients were started on a regular 
(monthly) transfusion regimen after the diagnosis of an ulcer; five were recorded as having their ulcer healed 
while in the others non-healing was documented, or healing was not documented.   
 
Platelet-rich plasma treatment in one small [26] and one relatively large study [33] was reported as associated 
with successful healing in many patients without recurrence.   
 
Granulocyte-macrophage colony-stimulating factor therapy has been associated with both partial [15] and 
complete [28] healing of leg ulcers.  Other systemic therapies have included, pentoxifylline combined with 
deferoxamine in a relatively large study in which reduced healing time was associated with recurrence [24]; and 
pentoxifylline alone, associated with complete, albeit short-term, healing [23].  In the only (other) study that had 
focused on ulcers in patients with HbE thalassemia, dilazep was associated with complete or partial healing in 
most [10].  Other treatments associated with complete or partial healing of ulcers in patients with thalassemia 
include hyperbaric oxygen therapy [22], arginine butyrate [25], hydroxyurea [27], and luspatercept [34].   
 
Conclusion 
This study, the largest to examine the complication in leg ulcers in any patients with any form of severe beta 
thalassemia, is also among the few to evaluate patients with HbE thalassemia; we could identify only one other 
study in the literature focused on this most common form of severe beta thalassemia.  We observed, in two large 
patient centres in Sri Lanka, that one in five evaluable patients with HbE thalassemia developed a leg ulcer over 
their clinical course.  This is a higher incidence than reported in other forms of beta thalassemia according to our 
review of a literature a review which was striking for the paucity of studies of leg ulcers in thalassemia, including 




Currently there is no clear benefit to any of the treatment approaches, of those attempted both in our study and 
other studies, for leg ulcers in thalassemia. Given both the broad and non-systematic nature of treatments 
explored in this retrospective study, as well as the relative paucity of other studies of leg ulcers in HbE 
thalassemia and in other forms of thalassemia, there is considerable difficulty in providing evidence-based 
recommendations for the treatment of leg ulcers in HbE thalassemia.  This gap in knowledge with respect to the 
optimal treatment of a complication, which from this study appears in HbE thalassemia to be relatively common, 
might be addressed in simple prospective comparative studies.  Controlled trials including of promising avenues 
of treatment planned or underway in studies of leg ulcers in sickle cell disease [8], might be undertaken to guide 
the best practices of care in this important, and common, complication.  From the data available in these patients 
and in the literature, we believe that a clinical trial comparing three promising therapies -- simple transfusions, 
platelet-rich plasma, and topical therapies -- might be considered.  While successful in some studies, treatment 
with G-CSF may be an impractical avenue of treatment in low-resource settings outside of a research study. 
 
In settings in which research studies may be impractical, we would recommend that the same three avenues of 
intervention: a short term (six month) regimen of monthly transfusions; or infusions of platelet-rich plasma; or 
systematic and careful toileting with topical therapies, should be considered.  Especially because one substantial 
limitation in the present analysis was that many treatment outcomes were undocumented, any treatment 
(transfusions, plasma or intensive topical therapies) should be evaluated before another treatment is added.  In 
this and the evaluation of other treatments for other complications, resources to improve systematic collection of 
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Figure and Table Legends 
Table 1.  Patient Characteristics at the Onset of a Leg Ulcer Onset and During Treatment for Ulcer 
Fig. 1. Age at first presentation of leg ulceration (N=45). Most patients were diagnosed with a leg ulcer between 
the ages of 20 and 29 years. 
Table 2. Patient Baseline Characteristics for 45 Patients with a Leg Ulcer, Compared to 151 Patients Without a 




















































37.3 ± 1.5 
[18-69] 
 
21 M  
24 F 
22.2 ± 1.4  
[5-49] 
On demand:  
55.6% 
≥8 Tx /year: 
15.6% 
<8 Tx /year:  
13.3% 
6.4 ± 0.2 
[3.4-8.9] 























Table 2.  Patient Baseline Characteristics for 45 Patients with a Leg Ulcer   
Compared to 151 Patients Without a Documented Leg Ulcer 
 






Odds Ratio p-value 95% CI 
N 45 151    
Age (years) 37.3 ± 1.6 
[18-69] 
 
23.1 ± 0.94 
[4-70] 
1.11 <0.001 1.07-1.15 



































1103 ± 139 
[57-4071] 
 

















13.3% 6.8% (n=147) 2.11 0.187 0.72-6.16 
  
